
{"id":19142,"date":"2022-01-10T09:00:09","date_gmt":"2022-01-10T09:00:09","guid":{"rendered":"https:\/\/dev2.btitrainingcenter.com\/plasma-rich-in-growth-factors-in-macular-hole-surgery\/"},"modified":"2026-01-09T16:25:41","modified_gmt":"2026-01-09T15:25:41","slug":"plasma-rich-in-growth-factors-in-macular-hole-surgery","status":"publish","type":"post","link":"https:\/\/www.btitrainingcenter.com\/it\/plasma-rich-in-growth-factors-in-macular-hole-surgery\/","title":{"rendered":"Plasma Rich in Growth Factors in Macular Hole Surgery"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row content_text_aligment=&#8221;left&#8221; row_background_lines=&#8221;no&#8221;][vc_column][vc_column_text]<\/p>\n<h3 class=\"title\">Abstract<\/h3>\n<div id=\"enc-abstract\" class=\"abstract-content selected\">\n<div id=\"enc-abstract\" class=\"abstract-content selected\">\n<div id=\"enc-abstract\" class=\"abstract-content selected\">\n<p>The aim of this study was to evaluate the use of PRGF (plasma rich in growth factors) as an adjuvant to PPV (pars plana vitrectomy) in recurrent, persistent, or poor prognosis MH (macular hole). Patients with MH were treated with PPV plus adjuvant therapy (PRGF membrane (mPRGF) and injectable liquid PRGF (iPRGF)). The anatomical closure of MH and postoperative BCVA (best-corrected visual acuity) were evaluated. Eight eyes (eight patients) were evaluated: myopic MH (MMH,\u00a0<i>n<\/i>\u00a0= 4), idiopathic MH (IMH,\u00a0<i>n<\/i>\u00a0= 2), iatrogenic\u00a0<i>n<\/i>\u00a0= 1, traumatic\u00a0<i>n<\/i>\u00a0= 1. The mean age was 53.1 \u00b1 19.3 years. Hence, 66.7% (<i>n<\/i>\u00a0= 4) of patients previously had internal limiting membrane peeling. Five patients (62.5%) received mPRGF and iPRGF, and three patients (37.5%) received iPRGF. Gas tamponade (C3F8) was placed in seven cases and one case of silicone oil. Anatomic closure of MH was achieved in seven eyes (87.5%) and BCVA improved in six cases. In the MMH group, visual acuity improved in two lines of vision. Follow-up time was 27.2 \u00b1 9.0 months. No adverse events or MH recurrences were recorded during follow-up. The use of PRGF as an adjuvant therapy to PPV can be useful to improve anatomical closure and visual acuity in MH surgery.<\/p>\n<\/div>\n<p><strong class=\"sub-title\">Keywords:\u00a0<\/strong>PRGF; macular hole; macular hole surgery; optical coherence tomography; retinal regeneration.<\/p>\n<\/div>\n<\/div>\n<p>[\/vc_column_text][vc_empty_space][vc_column_text]<\/p>\n<h3>Figures<\/h3>\n<p>[\/vc_column_text][vc_empty_space][\/vc_column][\/vc_row][vc_row content_placement=&#8221;middle&#8221; content_text_aligment=&#8221;center&#8221;][vc_column]<div class=\"qodef-image-gallery qodef-grid-list qodef-disable-bottom-space  qodef-ig-grid-type qodef-four-columns qodef-tiny-space  qodef-image-behavior-lightbox\">\n\t<div class=\"qodef-ig-inner qodef-outer-space\">\n\t\t\t\t\t<div class=\"qodef-ig-image qodef-item-space\">\n\t\t\t\t<div class=\"qodef-ig-image-inner\">\n\t\t\t\t\t\t\t\t\t\t\t<a itemprop=\"image\" class=\"qodef-ig-lightbox\" href=\"https:\/\/www.btitrainingcenter.com\/wp-content\/uploads\/2021\/08\/clinpract-12-00007-g001.jpg\" data-rel=\"prettyPhoto[image_gallery_pretty_photo-625]\" title=\"&lt;strong&gt;Figure 01:&lt;\/strong&gt; Result in visual acuity due to the use of PRGF in macular hole surgery. Description of changes in visual acuity according to the type of macular hole. PRGF: Plasma Rich in Growth Factors, BCVA: Best Corrected Visual Acuity, MMH: Myopic Macular Hole, IMH: Idiopathic Macular Hole.\">\n\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.btitrainingcenter.com\/wp-content\/uploads\/2021\/08\/clinpract-12-00007-g001-200x200.jpg\" alt=\"\" width=\"200\" height=\"200\" \/>\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class=\"qodef-ig-image qodef-item-space\">\n\t\t\t\t<div class=\"qodef-ig-image-inner\">\n\t\t\t\t\t\t\t\t\t\t\t<a itemprop=\"image\" class=\"qodef-ig-lightbox\" href=\"https:\/\/www.btitrainingcenter.com\/wp-content\/uploads\/2021\/08\/clinpract-12-00007-g002.jpg\" data-rel=\"prettyPhoto[image_gallery_pretty_photo-625]\" title=\"&lt;strong&gt;Figure 02&lt;\/strong&gt; Patient number 2 diagnosed with recurrent MMH (myopic macular hole) with two previous failed PPV (Pars Plana Vitrectomy). (A) Retinography of recurrent MMH with 63 months of evolution, before surgery with Plasma Rich in Growth Factors liquid injection (iPRGF). (B)Pre-surgical optical coherence tomography (OCT) of MMH. (C) OCT macular image one month after surgery. (D) OCT at six months follow-up, restoration of the (ELM) External Limiting Membrane (red arrow) and the ellipsoid layer (yellow arrow) is observed, leaving a small cyst at the central foveal level. (E) OCT at twelve months of follow-up, the formation of the ELM (red arrow) is observed. (F) Retinography at the end of follow-up (29.5 months).\">\n\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.btitrainingcenter.com\/wp-content\/uploads\/2021\/08\/clinpract-12-00007-g002-200x200.jpg\" alt=\"\" width=\"200\" height=\"200\" \/>\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class=\"qodef-ig-image qodef-item-space\">\n\t\t\t\t<div class=\"qodef-ig-image-inner\">\n\t\t\t\t\t\t\t\t\t\t\t<a itemprop=\"image\" class=\"qodef-ig-lightbox\" href=\"https:\/\/www.btitrainingcenter.com\/wp-content\/uploads\/2021\/08\/clinpract-12-00007-g003.jpg\" data-rel=\"prettyPhoto[image_gallery_pretty_photo-625]\" title=\"&lt;strong&gt;Figure 03&lt;\/strong&gt; Patient number 6 diagnosed with a large idiopathic macular hole (IMH) without prior PPV (Pars Plana Vitrectomy). (A) Presurgical retinography of IMH in Gass stage 4 and &gt;400 \u00b5m minimum diameter. (B) The initial optical coherence tomography (OCT) image shows a large IMH with multiple cystic spaces. (C) Image of macular OCT one month after surgery (injectable liquid and membrane PRGF were used as an adjuvant to PPV) shows the closed IMH and the start of the formation of ELM (External Limiting Membrane) (red arrow). (D) OCT two months post-surgery shows the formation of the ELM (red arrow) and initiates restoration of the ellipsoid layer (yellow arrow). (E) OCT seven months post-surgery shows the complete formation of the ELM (red arrow) at the foveal level with a lack of continuity in the ellipsoid layer (yellow arrow). (F) OCT 24 months post-surgery, the complete formation of the ELM (red arrow) and ellipsoid layer (yellow arrow) is observed. (G) OCT 35.5 months post-surgery, patient with final BCVA of 1.0 decimal (0.000 LogMar). (H) Retinography at the end of follow-up: no clinical evidence of IMH.\">\n\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.btitrainingcenter.com\/wp-content\/uploads\/2021\/08\/clinpract-12-00007-g003-200x200.jpg\" alt=\"\" width=\"200\" height=\"200\" \/>\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<div class=\"qodef-ig-image qodef-item-space\">\n\t\t\t\t<div class=\"qodef-ig-image-inner\">\n\t\t\t\t\t\t\t\t\t\t\t<a itemprop=\"image\" class=\"qodef-ig-lightbox\" href=\"https:\/\/www.btitrainingcenter.com\/wp-content\/uploads\/2021\/08\/clinpract-12-00007-g004.jpg\" data-rel=\"prettyPhoto[image_gallery_pretty_photo-625]\" title=\"&lt;strong&gt;Figure 04&lt;\/strong&gt; Patient number 8 with a Diagnosis of traumatic macular hole (TMH). (A) Retinography that shows chronic changes in the TMH of six months of evolution, no surgery has been performed. (B) Optical coherence tomography pre-surgical OCT. The initial BCVA (Best Corrected Visual Acuity) was 0.05 decimal (1301 LogMar), injectable liquid and PRGF membrane are used as adjuvants in PPV (Pars Plana Vitrectomy). (C) OCT one month after surgery. TMH closure observed. (D) OCT three months post-surgical. The segmented restoration of the External Limiting Membrane (ELM) (red arrow) and of the ellipsoid layer (yellow arrow) is observed. (E) OCT image at twelve months post-surgical follow-up, thinning of the inner layers of the retina is observed, the restoration of the ELM (red arrow) and the ellipsoid layer (yellow arrow) is maintained. (F) Fundus photography taken with Optomap at 35.8 months of follow-up, TMH closure is maintained, and BVCA is recovered at 0.6 decimal (0.222 LogMar).\">\n\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.btitrainingcenter.com\/wp-content\/uploads\/2021\/08\/clinpract-12-00007-g004-200x200.jpg\" alt=\"\" width=\"200\" height=\"200\" \/>\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t<\/div>\n<\/div>[vc_empty_space height=&#8221;50px&#8221;][\/vc_column][\/vc_row][vc_row][vc_column]<a itemprop=\"url\" href=\"\/wp-content\/uploads\/2021\/08\/clinpract-12-00007.pdf\" target=\"_blank\"  class=\"qodef-btn qodef-btn-medium qodef-btn-solid btnWebRosa2\"  >\n    <span class=\"qodef-btn-text\">Scarica articolo<\/span>\n    <\/a>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p><strong>Clin Pract. 2022 Jan 10;12(1):57-69.<\/strong> The aim of this study was to evaluate the use of PRGF (plasma rich in growth factors) as an adjuvant to PPV (pars plana vitrectomy) in recurrent, persistent, or poor prognosis MH (macular hole). Patients with MH were treated with PPV plus adjuvant therapy (PRGF membrane (mPRGF) and injectable liquid PRGF (iPRGF)). <\/p>\n","protected":false},"author":1,"featured_media":19137,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[157],"tags":[413,414,415,416],"class_list":["post-19142","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicina-rigenerativa","tag-apnea-it","tag-implantologia-it","tag-medicina-it","tag-salud-it"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/posts\/19142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/comments?post=19142"}],"version-history":[{"count":2,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/posts\/19142\/revisions"}],"predecessor-version":[{"id":45147,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/posts\/19142\/revisions\/45147"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/media\/19137"}],"wp:attachment":[{"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/media?parent=19142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/categories?post=19142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/tags?post=19142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}